<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46848">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01830127</url>
  </required_header>
  <id_info>
    <org_study_id>1241.30</org_study_id>
    <secondary_id>2012-003534-17</secondary_id>
    <nct_id>NCT01830127</nct_id>
  </id_info>
  <brief_title>BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3</brief_title>
  <official_title>A Phase III Randomised, Double-blind and Placebo-controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Patients With Moderate Hepatic Impairment (Child-Pugh B) With Genotype 1b Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cohort A: Objective of Part 1a:  to assess the pharmacokenetic characteristics of  600 mg
      BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected
      patients with mild hepatic impairment (CPA) (Arm 1) versus 400 mg BID BI 207127 / 120 mg QD
      faldaprevir /ribavirin in a small number of GT1b HCV infected patients with moderate hepatic
      impairment (CPB) (Arm 2).

      Cohort A: Objective of Part 1b (Arm 3): Part 1b will only be conducted if the
      pharmacokenetics in Part 1a show that the 400 mg BID BI 207127 / 120 mg QD faldaprevir /
      ribavirin regimen is inadequate to achieve therapeutic BI207127 and/or faldaprevir levels.
      Part 1B will assess the pharmacokenetic characteristics of 600 mg BID BI 207127  / 120 mg QD
      faldaprevir /ribavirin in a small number of GT1b HCV infected patients with moderate hepatic
      impairment (CPB). If arm 2 in part 1a has similar or higher PK than Arm 1, Part 1b (Arm 3)
      will be skipped.

      Cohort B: Main Objective Part 2:  To evaluate the safety, efficacy and PK of treatment with
      120 mg of once daily (QD) faldaprevir for 24 weeks in combination with either 400 mg of
      twice-daily (BID) BI 207127 or 600 mg of BID BI 207127 (depending on the outcome of Part 1)
      and ribavirin (R) in a larger group of GT1b HCV infected patients with moderate hepatic
      impairment (CPB).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>SVR12:  Plasma HCV RNA level less than 25 IU/mL at 12 weeks after End of Treatment</measure>
    <time_frame>12 weeks after End of Treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>SVR4:  Plasma HCV RNA level less than 25 IU/mL at 4 weeks after End of Treatment</measure>
    <time_frame>4 weeks after End of Treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR24:  Plasma HCV RNA level less than 25 IU/mL at 24 weeks after End of Treatment</measure>
    <time_frame>24 week after End of Treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>cohort a CPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A CPA high dose BID BI 207127/QD Faldaprevir and ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort a CPB low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A CPB low dose BID BI 207127/QD Faldaprevir and ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort a CPB high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A CPB high dose BID BI 207127/QD Faldaprevir and ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort b control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort B CPB placebo control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort b active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B CPB BID BI 207127/QD Faldaprevir and ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faldaprevir</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort a CPB high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort b active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 high dose</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort a CPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faldaprevir</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort b control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 high dose</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort a CPB high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin placebo</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort a CPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort b control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faldaprevir</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort b active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 high dose placebo</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort a CPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faldaprevir</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort a CPB low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faldaprevir placebo</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort a CPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 low dose</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort a CPB low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort a CPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 low dose placebo</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort a CPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faldaprevir</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort a CPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 low dose</intervention_name>
    <description>24 weeks</description>
    <arm_group_label>cohort a CPA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Treatment na√Øve and treatment experienced patients (prior relapse, interferon
             intolerant, and [allowed in Cohort A only] prior partial response).

          2. Chronic HCV infection of genotype 1 (GT1), sub-GT1b virus only.

          3. Liver cirrhosis defined as Metavir Grade=4 or Ishak Grade =5 on liver biopsy or liver
             stiffness of  =13 kPa on fibroscan.

        Exclusion criteria:

          1. HCV infection of mixed genotype (1/2, 1/3, and 1/4) or mixed sub-GT1a/1b or undefined
             diagnosed by genotypic testing at screening

          2. Liver disease due to causes other than chronic HCV infection which may include but is
             not limited to hemochromatosis, Wilson's disease, or autoimmune liver diseases.

          3. HIV infection

          4. Patients who have been previously treated with an investigational or approved DAA
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1241.30.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.10007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.10012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.10011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.10002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.30.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Ireland</country>
    <country>Switzerland</country>
    <country>France</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>March 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
